BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23861105)

  • 1. Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.
    Wu SJ; Tang JL; Lin CT; Kuo YY; Li LY; Tseng MH; Huang CF; Lai YJ; Lee FY; Liu MC; Liu CW; Hou HA; Chen CY; Chou WC; Yao M; Huang SY; Ko BS; Tsay W; Tien HF
    Am J Hematol; 2013 Nov; 88(11):E277-82. PubMed ID: 23861105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
    Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
    Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Qian J; Yao DM; Lin J; Qian W; Wang CZ; Chai HY; Yang J; Li Y; Deng ZQ; Ma JC; Chen XX
    PLoS One; 2012; 7(9):e45760. PubMed ID: 23029227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome.
    Wang H; Guo Y; Dong Z; Li T; Xie X; Wan D; Jiang Z; Yu J; Guo R
    Sci Rep; 2020 Oct; 10(1):18622. PubMed ID: 33122737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
    Hou HA; Kuo YY; Tang JL; Chou WC; Yao M; Lai YJ; Lin CC; Chen CY; Liu CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Feb; 89(2):181-6. PubMed ID: 24127063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
    Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
    Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
    Hamilton BK; Visconte V; Jia X; Tabarroki A; Makishima H; Hasrouni E; Abounader D; Kalaycio M; Sekeres MA; Sobecks R; Duong Liu H; Bolwell B; Maciejewski JP; Copelan E; Tiu RV
    Am J Hematol; 2016 Jun; 91(4):406-9. PubMed ID: 26799334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.
    Graubert TA; Shen D; Ding L; Okeyo-Owuor T; Lunn CL; Shao J; Krysiak K; Harris CC; Koboldt DC; Larson DE; McLellan MD; Dooling DJ; Abbott RM; Fulton RS; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Grillot M; Baty J; Heath S; Frater JL; Nasim T; Link DC; Tomasson MH; Westervelt P; DiPersio JF; Mardis ER; Ley TJ; Wilson RK; Walter MJ
    Nat Genet; 2011 Dec; 44(1):53-7. PubMed ID: 22158538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis.
    Wang H; Zhang N; Wu X; Zheng X; Ling Y; Gong Y
    Ann Hematol; 2019 Dec; 98(12):2629-2639. PubMed ID: 31754743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
    Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
    Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
    Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH
    Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes.
    Li B; Liu J; Jia Y; Wang J; Xu Z; Qin T; Shi Z; Song Z; Peng S; Huang H; Fang L; Zhang H; Pan L; Hu N; Qu S; Zhang Y; Wu J; Liu N; Ru K; Huang G; Xiao Z
    Genes Chromosomes Cancer; 2018 Feb; 57(2):80-88. PubMed ID: 29057546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.
    Shirai CL; Ley JN; White BS; Kim S; Tibbitts J; Shao J; Ndonwi M; Wadugu B; Duncavage EJ; Okeyo-Owuor T; Liu T; Griffith M; McGrath S; Magrini V; Fulton RS; Fronick C; O'Laughlin M; Graubert TA; Walter MJ
    Cancer Cell; 2015 May; 27(5):631-43. PubMed ID: 25965570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis.
    Wang X; Song X; Yan X
    Medicine (Baltimore); 2019 May; 98(21):e15743. PubMed ID: 31124956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
    Lin CC; Hou HA; Chou WC; Kuo YY; Liu CY; Chen CY; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Feb; 89(2):137-44. PubMed ID: 24115220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing.
    Okeyo-Owuor T; White BS; Chatrikhi R; Mohan DR; Kim S; Griffith M; Ding L; Ketkar-Kulkarni S; Hundal J; Laird KM; Kielkopf CL; Ley TJ; Walter MJ; Graubert TA
    Leukemia; 2015 Apr; 29(4):909-17. PubMed ID: 25311244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
    Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
    Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution.
    Wu SJ; Kuo YY; Hou HA; Li LY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Lin CT; Chen CY; Chou WC; Yao M; Huang SY; Ko BS; Tang JL; Tsay W; Tien HF
    Blood; 2012 Oct; 120(15):3106-11. PubMed ID: 22932795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.